

CÔNG TY CỔ PHẦN DƯỢC PHẨM
HÀ TÂY

CỘNG HÒA XÃ HỘI CHỦ NGHĨA VIỆT NAM

Số: 640 /CV-DHT

Độc lập - Tự do - Hạnh phúc

Hà Nội, ngày 28 tháng 07 năm 2026

CÔNG BỐ THÔNG TIN ĐỊNH KỲ BÁO CÁO TÀI CHÍNH

Kính gửi: Sở Giao dịch Chứng khoán Hà Nội

Thực hiện quy định tại Khoản 3 Điều 14 Thông tư số 96/2020/TT-BTC ngày 16/11/2020 của Bộ Tài chính hướng dẫn công bố thông tin trên thị trường chứng khoán, CTCP Dược phẩm Hà Tây thực hiện công bố thông tin báo cáo tài chính (BCTC) quý 2/năm 2026 với Sở Giao dịch Chứng khoán Hà Nội như sau:

1. Tên tổ chức: CÔNG TY CỔ PHẦN DƯỢC PHẨM HÀ TÂY

- Mã chứng khoán: DHT
- Địa chỉ: Số 10A phố Quang Trung, phường Hà Đông, TP. Hà Nội
- Điện thoại liên hệ/Tel: 0433 501 117 Fax:
- Email: duochatay@gmail.com
- Website: <https://www.hataphar.com.vn>

2. Nội dung thông tin công bố:

- BCTC quý 2/năm 2026

☒ BCTC riêng (TCNY không có công ty con và đơn vị kế toán cấp trên có đơn vị trực thuộc);

☒ BCTC hợp nhất (TCNY có công ty con);

☐ BCTC tổng hợp (TCNY có đơn vị kế toán trực thuộc tổ chức bộ máy kế toán riêng).

- Các trường hợp thuộc diện phải giải trình nguyên nhân:

+ Tổ chức kiểm toán đưa ra ý kiến không phải là ý kiến chấp nhận toàn phần đối với BCTC (đối với BCTC được soát xét/được kiểm toán):

☐ Có

☒ Không

Văn bản giải trình trong trường hợp tích có:

☐ Có

☐ Không

+ Lợi nhuận sau thuế trong kỳ báo cáo có sự chênh lệch trước và sau kiểm toán từ 5% trở lên, chuyển từ lỗ sang lãi hoặc ngược lại (đối với BCTC được kiểm toán năm 2026):

☐ Có

☒ Không



Văn bản giải trình trong trường hợp tích có:

☐ Có

☐ Không

+ Lợi nhuận sau thuế thu nhập doanh nghiệp tại báo cáo kết quả kinh doanh của kỳ báo cáo thay đổi từ 10% trở lên so với báo cáo cùng kỳ năm trước:

☒ Có

☐ Không

Văn bản giải trình trong trường hợp tích có:

☒ Có

☐ Không

+ Lợi nhuận sau thuế trong kỳ báo cáo bị lỗ, chuyển từ lãi ở báo cáo cùng kỳ năm trước sang lỗ ở kỳ này hoặc ngược lại:

☐ Có

☒ Không

Văn bản giải trình trong trường hợp tích có:

☐ Có

☐ Không

Thông tin này đã được công bố trên trang thông tin điện tử của công ty vào ngày: 28/07/2026 tại đường dẫn: <https://www.hataphar.com.vn/thong-tin-codong.html>3.

3. Báo cáo về các giao dịch có giá trị từ 35% tổng tài sản trở lên trong năm 2026: Không có

Trường hợp TCNY có giao dịch đề nghị báo cáo đầy đủ các nội dung sau:

- Nội dung giao dịch:
- Tỷ trọng giá trị giao dịch/tổng giá trị tài sản của doanh nghiệp (%) (căn cứ trên báo cáo tài chính năm gần nhất):
- Ngày hoàn thành giao dịch

Chúng tôi xin cam kết các thông tin công bố trên đây là đúng sự thật và hoàn toàn chịu trách nhiệm trước pháp luật về nội dung các thông tin công bố.

Tài liệu đính kèm:

- BCTC riêng Quý 2.2026
- BCTC HN Quý 2.2026
- Văn bản giải trình

Đại diện tổ chức
Người đại diện theo pháp luật/Người UQCBTT
(Ký, ghi rõ họ tên, chức vụ, đóng dấu)



TỔNG GIÁM ĐỐC
OSAMU YOMOGIDA



No. *68*/CV-BCTC-DHT

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom - Happiness

Hanoi, July 28, 2026

To: The State Securities Commission of Viet Nam
Hanoi Stock Exchange

Company name: Ha Tay Pharmaceutical Joint Stock Company

Stock Code: DHT

Head office: 10A Quang Trung – Ha Dong Ward – Hanoi City

Phone: 0433 501 117 – Fax: 0433 829 054

Information disclosure officer: Mrs. Pham Minh Thu – Deputy Manager of Legal and Communications Department.

In the Consolidated financial statements for Q2 2026, the business results of Hatay Pharmaceutical Joint Stock Company are as follows:

The total profit after tax in Q2 2026 was VND 11.409.975.718, compared to VND 13.408.687.822 in Q2 2025 — a decrease of VND 1.998.712.104, equivalent to a drop of 14.91% This was mainly due to:

- Gross profit in the Q2 in 2026 amounted to VND 51,319,928,919, compared to VND 51,099,341,904 in the Q2 in 2025, representing an increase of VND 220,587,015.
- Financial income in the Q2 in 2026 amounted to VND 4,640,393,405, compared to VND 5,660,632,622 in the Q2 in 2025, representing a decrease of VND 1,020,239,217, or 18.02%. The decline in financial income had an adverse impact on the Company's profit for the period.
- Selling expenses and general and administrative expenses in the Q2 in 2026 totaled VND 40,945,408,110, compared to VND 36,921,558,738 in the Q2 in 2025, representing an increase of VND 4,023,849,372, or 11%. The increase in selling expenses and general and administrative expenses negatively affected the Company's profit for the period.
- Corporate income tax expense for the Q2 in 2026 amounted to VND 3,632,813,461, compared to VND 2,928,429,738 in the Q2 in 2025, representing an increase of VND 704,383,723, or 24%. The higher corporate income tax expense reduced the Company's profit after tax for the period.

We hereby report to the State Securities Commission of Vietnam and the Hanoi Stock Exchange for your information.

Recipient:

- As above
- Archive: Office files

HA TAY PHARMACEUTICAL JOINT STOCK
COMPANY

General Director



Osamu Yomogida
Osamu Yomogida

HATAY PHARMACEUTICAL JOINT STOCK COMPANY
CONSOLIDATED FINANCIAL STATEMENTS

For the period from 01/04/2026 to 30/06/2026

Form B 01 - DN/HN

CONSOLIDATED BALANCE SHEET

As at June 30, 2026

				Unit: VND
ASSETS	Codes	Notes	30/6/2026	01/01/2026 (Reclassification)
A - CURRENT ASSETS	100		689,600,287,571	896,739,416,323
I. Cash and cash equivalents	110	V.01	64,785,701,868	84,407,566,361
1 Cash	111		49,285,701,868	74,036,751,569
2 Cash equivalents	112		15,500,000,000	10,370,814,792
II. Short-term financial investments	120		102,549,534,200	153,045,424,635
1 Held-to-maturity investments	123	V.02	102,549,534,200	153,045,424,635
III. Short-term receivables	130		154,489,106,973	145,889,465,780
1 Short-term trade receivables	131	V.03	115,370,564,562	111,636,095,800
2 Short-term advances to suppliers	132	V.04	42,456,270,278	37,840,076,173
3 Other short-term receivables	136	V.05	474,879,091	294,439,301
4 Provision for short-term doubtful debts	137	V.06	(3,812,606,958)	(3,881,145,494)
IV. Inventories	140	V.07	366,876,862,398	513,396,959,547
1 Inventories	141		366,876,862,398	513,396,959,547
V. Current biological assets	150		-	-
VI. Other current assets	160		899,082,132	-
1 Deductible VAT	162		899,082,132	-
B - NON-CURRENT ASSETS	200		1,033,602,230,077	1,035,177,856,096
I. Long-term receivables	210		6,407,042,500	6,407,042,500
1 Other long-term receivables	215	V.05	6,407,042,500	6,407,042,500
II. Fixed assets	220		163,689,314,373	174,908,301,066
1 Tangible fixed assets	221	V.08	162,312,654,373	173,531,641,066
Cost	222		444,246,675,571	446,492,048,355
Accumulated depreciation	223		(281,934,021,198)	(272,960,407,289)
2 Intangible fixed assets	227	V.09	1,376,660,000	1,376,660,000
Cost	228		2,026,660,000	2,026,660,000
Accumulated amortization	229		(650,000,000)	(650,000,000)
III. Non-current biological assets	230		-	-
IV. Long-term assets in progress	240		-	-
V. Construction work in progress	250		822,030,943,108	827,184,318,661
1 Construction in progress	252	V.10	822,030,943,108	827,184,318,661
VI. Long-term financial investments	260	V.02	20,241,206,443	19,860,292,957
1 Investment in joint-ventures, associates	262		20,241,206,443	19,860,292,957
VII. Other long-term assets	270		21,233,723,653	6,817,900,912
1 Long-term prepayments expenses	271	V.11	20,190,389,980	5,632,174,250
2 Deferred tax assets	272	V.12	1,043,333,673	1,185,726,662
TOTAL ASSETS (280=100+200)	280		1,723,202,517,648	1,931,917,272,419

Form B 01 - DN/HN

CONSOLIDATED BALANCE SHEET

As at June 30, 2026

(continued)

Unit: VND

RESOURCES	Codes	Notes	30/6/2026	01/01/2026 (Reclassification)
C - LIABILITIES	300		592,225,826,665	820,716,628,095
I. Current liabilities	310		505,670,679,118	734,022,780,548
1 Short - term trade payables	311	V.13	209,312,093,810	261,260,793,034
2 Short - term advances from customers	312	V.14	105,646,454,510	177,983,077,668
3 Taxes and amounts payable to the State budget	314	V.15	3,321,108,060	5,515,053,039
4 Payables to employees	315		18,405,752,780	28,051,603,241
5 Short-term accrued expenses	316	V.16	96,289,965	161,520,303
6 Short-term unearned revenue	319	V.17	5,706,724,086	6,418,086,306
7 Other current payables	320	V.18	1,491,269,039	783,924,677
8 Short-term loans and obligations under finance	321	V.19	160,648,306,796	249,995,403,408
9 Bonus and welfare funds	323		1,042,680,072	3,853,318,872
II. Long-term liabilities	330		86,555,147,547	86,693,847,547
1 Other long-term payables	338	V.18	3,486,900,000	3,625,600,000
2 Long-term loans and obligations under finance leases	339	V.19	83,068,247,547	83,068,247,547
D - EQUITY	400		1,130,976,690,983	1,111,200,644,324
I. Owner's contributed capital	410	V.20	1,130,976,690,983	1,111,200,644,324
1 Owner's contributed capital	411		905,755,510,000	905,755,510,000
- Ordinary shares carrying voting rights	411a		905,755,510,000	905,755,510,000
2 Share premium	412		37,282,220,000	37,282,220,000
3 Other owners' equity	414		2,236,413,529	26,612,306,630
4 Treasury shares	415		(8,083,874,357)	(8,083,874,357)
5 Investment and development fund	418		10,749,248,213	10,749,248,213
6 Retained earnings	420		155,106,685,445	110,355,967,042
- Retained earnings accumulated to the prior year end	420a		134,116,766,080	56,699,133,435
- Retained earnings of current year	420b		20,989,919,365	53,656,833,607
7 Non-controlling interest	429		27,930,488,153	28,529,266,796
TOTAL RESOURCES (440=300+400)	440		1,723,202,517,648	1,931,917,272,419

Hanoi, July 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by


Chief Accountant

General Director

Nguyen Hai Trieu

Dinh Nam Ha

Osamu Yomogida



CONSOLIDATED INCOME STATEMENT

For the period from 01/04/2026 to 30/06/2026

Unit: VND

ITEMS	Code s	Notes	Quarter II		Year 2026	Year 2025
			Year 2026	Year 2025		
1 Gross revenue from goods sold and services rendered	01	II.1	575,939,699,624	574,560,123,544	1,144,796,344,712	1,070,569,562,879
2 Deductions	02	II.2	19,904,762	209,032,070	48,975,762	209,869,070
3 Net revenue from goods sold and services rendered (10=01-02)	10	II.3	575,919,794,862	574,351,091,474	1,144,747,368,950	1,070,359,693,809
4 Cost of sales	11	II.4	524,599,865,943	523,251,749,570	1,054,639,682,733	963,034,045,601
5 Gross profit from goods sold and services rendered (20=10-11)	20		51,319,928,919	51,099,341,904	90,107,686,217	107,325,648,208
6 Gain/(loss) on sale and disposal of investment property	21		-	-	-	-
7 Financial income	22	II.5	4,640,393,405	5,660,632,622	12,186,945,882	16,272,793,859
8 Financial expenses	23	II.6	3,390,334,927	9,447,239,102	6,527,240,650	13,245,813,064
In which: Interest expense	24		2,880,294,497	3,430,297,452	5,758,663,193	7,127,225,787
9 Selling expenses	25	II.9	11,199,570,753	8,431,676,250	23,709,341,492	15,716,331,981
10 General and administration expenses	26	II.9	29,745,837,357	28,489,882,488	53,649,843,979	60,775,790,178
11 Profit or loss from associates, joint ventures	27		342,963,379	2,156,368,964	996,007,549	4,989,433,485
12 Operating profit {30 = 20 + (21 - 22) + 24 - (25 + 26)}	30		11,967,542,666	12,547,545,650	19,404,213,527	38,849,940,329
13 Other income	31	II.7	3,479,113,615	3,790,770,741	7,119,670,306	7,453,240,653
14 Other expenses	32	II.8	771,185,302	1,198,831	775,105,726	630,379,075
15 Profit from other activities (40=31-32)	40		2,707,928,313	3,789,571,910	6,344,564,580	6,822,861,578

16	Accounting profit before tax (50=30+ 40)	50		16,337,117,560	25,748,778,107	45,672,801,907
17	Current CIT expense	51	II.10	2,928,429,738	5,215,244,396	8,352,860,985
18	Deferred CIT expense	52		-	142,392,989	-
19	Net profit after corporate income tax (60=50-51-52)	60		13,408,687,822	20,391,140,722	37,319,940,922
20	The Parent company's net profit after tax	61		13,185,055,359	20,989,919,365	34,485,901,629
21	The non-controlling interests shareholders' net profit :	62		223,632,463	(598,778,643)	2,834,039,293

Hanoi, July 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Prepared by

Nguyen Hai Tricu

Nguyen Hai Tricu

Chief Accountant

Dinh Nam Ha

Dinh Nam Ha

General Director



Osamu Yomogida

Osamu Yomogida

CONSOLIDATED CASH FLOWS STATEMENT

(Under indirect method)

For the period from 01/04/2026 to 30/06/2026

ITEMS	Cod es	Notes	Quarter II		Year 2026	Year 2025	Unit: VND Year 2025
			Year 2026	Year 2025			
I. Cash flow from operating activities							
1. Profit before tax	01		14,675,470,979	16,337,117,560	25,748,778,107	45,672,801,907	
2. Adjustments for							
- Depreciation of fixed assets and investment properties	02		6,183,282,936	5,948,299,520	12,360,112,693	11,930,613,214	
- Provisions	03		(68,538,536)	212,849,489	(68,538,536)	212,849,489	
- Foreign exchange loss/gain arising from translating foreign currency items	04		(987,481,174)	5,299,727,203	(987,481,174)	5,299,727,203	
- Gain, loss from investing activities	05		(6,971,513,342)	(2,888,899,506)	(4,342,388,324)	(12,925,105,580)	
- Interest expense	06		2,880,294,497	3,430,297,452	5,758,663,193	7,127,225,787	
3. Profit from operating activities before changes in working capital	08		15,711,515,360	28,339,391,718	38,469,145,959	57,318,112,020	
- Increases/Decreases in receivables	09		(14,963,326,798)	(62,448,659,751)	(9,430,184,789)	8,970,502,024	
- Increases/Decreases in inventories	10		20,277,828,629	904,263,033	146,520,097,149	(23,684,158,516)	
- Increases/Decreases in payables (excluding interest payable, corporate income tax payable)	11		17,075,889,945	98,272,860,270	(134,427,096,080)	98,493,753,748	
- Increases/Decreases in prepayment expense	12		(2,055,441,299)	214,748,378	(1,598,308,200)	259,256,417	
- Interest expense paid	14		(8,496,391,772)	(2,502,407,445)	(5,823,893,531)	(7,173,238,312)	
- Corporate income tax paid	15		(2,142,955,532)	(5,424,431,247)	(6,693,175,871)	(10,494,507,962)	
- Other cash inflows	16		(148,700,000)	-	-	-	
- Other cash outflows	17		(137,440,000)	(177,662,877)	(2,810,638,800)	(178,962,877)	
Net cash flow from operating activities	20		25,120,978,533	57,178,102,079	24,205,945,837	123,510,756,542	
II. Cash flow from investing activities							
1. Acquisition and construction of fixed assets and other non-	21		866,307,482	(19,315,893,497)	(8,947,657,977)	(40,457,863,446)	
2. Proceeds from sale, disposal of fixed assets and other non-	22		-	63,636,364	-	113,636,364	

3. Cash outflows for lending, buying debt instruments of other	23	(120,000,000,000)	(10,000,000,000)	(120,000,000,000)	(70,000,000,000)
4. Cash recovered from lending, selling debt instruments of other	24	80,000,000,000	80,000,000,000	170,000,000,000	90,000,000,000
5. Cash recovered from lending, selling debt instruments of other entities	26	-	-	-	8,000,000,000
6. Interest earned, dividends and profits received	27	4,210,723,652	1,976,625,554	4,528,180,065	3,262,039,654
Net cash flow from investment activities	30	(34,922,968,866)	52,724,368,421	45,580,522,088	(9,082,187,428)
III. Cash flow from financial activities					
1. Proceeds from borrowing	33	65,472,759,527	221,332,140,167	208,735,041,876	381,263,054,367
2. Repayment of borrowing	34	(129,375,279,434)	(237,891,759,730)	(298,082,138,488)	(428,844,873,182)
5. Dividends and profits paid	35	-	-	-	-
Net cash flow from financial activities	40	(63,902,519,907)	(16,559,619,563)	(89,347,096,612)	(47,581,818,815)
Net cash flow in the period (50 = 20+30+40)	50	(73,704,510,240)	93,342,850,937	(19,560,628,687)	66,846,750,299
Cash and cash equivalents at the beginning of the year	60	138,480,633,122	63,773,572,235	84,336,751,569	90,269,672,873
Effect of changes in foreign exchange rates	61	9,578,986	657,432	9,578,986	657,432
Cash and cash equivalents at the end of the year (70 = 50+60+61)	70	64,785,701,868	157,117,080,604	64,785,701,868	157,117,080,604

Hanoi, July 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Chief Accountant

General Director



Prepared by

Nguyen Hai Trieu

Nguyen Hai Trieu

Dinh Nam Ha

Osamu Yomogida

Osamu Yomogida

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

I. Additional information of items presented in the Consolidated Balance Sheet

1. Cash and cash equivalents

	30/6/2026	01/01/2026
	VND	VND
Cash	49,285,701,868	74,036,751,569
<i>Cash on hand</i>	<i>5,337,046,561</i>	<i>5,265,522,207</i>
<i>Cash in bank</i>	<i>43,948,655,307</i>	<i>68,771,229,362</i>
VND	43,691,064,659	68,646,493,402
USD	246,815,342	113,685,066
EUR	10,775,306	11,050,894
Cash equivalents (*)	15,500,000,000	10,370,814,792
Bank deposits with terms of less than 3 months	15,500,000,000	10,370,814,792
Total	64,785,701,868	84,407,566,361

(*) Represents deposit contracts with maturities of no more than three months placed with Viet A Commercial Joint Stock Bank – Ha Dong Branch.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)*(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)***2. Financial investments****a) Held-to-maturity investments**

	30/6/2026		01/01/2026 (Reclassification)		
	Cost	Recoverable amount	Provision	Giá gốc Recoverable amount	Provision
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh	-	-	-	81,904,219,178	81,904,219,178
Viet A Joint Stock Commercial Bank – Ha Dong Branch (2)	81,763,232,830	81,763,232,830	-	30,546,356,141	30,546,356,141
Vietnam Technological and Commercial Joint Stock Bank – Dong Do Branch (3)	20,786,301,370	20,786,301,370	-	40,594,849,316	40,594,849,316
Total	102,549,534,200	102,549,534,200	-	153,045,424,635	153,045,424,635

(1) Pursuant to Term Deposit Agreement No. 320/2025/21810 dated 3 July 2025, the Company placed a term deposit of VND 80 billion with a term of six months, bearing interest at 4.8% per annum, with interest payable at maturity.

(2) Comprises term deposit agreements with a six-month maturity, bearing interest at rates ranging from 8.0% to 8.7% per annum, with interest payable at maturity.

(3) Pursuant to Term Deposit Agreement No. 14588888368035/TGKH/TCB dated 7 January 2026, the Company placed a term deposit of VND 20 billion with a term of six months, bearing interest at 8.2% per annum, with principal and interest payable at maturity.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)*(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)***b) Capital contribution into other entities**

	30/6/2026			01/01/2026		
	VND			VND		
	Cost	Adjustments during the period	Carrying amount	Cost	Adjustments during the period	Carrying amount
<i>Investment into subsidiaries</i>						
Southern Hataphar Company Limited (i)	700,000,000	256,814,139	956,814,139	700,000,000	124,961,667	824,961,667
Vietnam Hataphar Healthcare High Technology Pharmaceutical Joint Stock Company (ii)	2,450,000,000	16,834,392,304	19,284,392,304	2,450,000,000	16,585,331,290	19,035,331,290
Total	3,150,000,000	17,091,206,443	20,241,206,443	3,150,000,000	16,710,292,957	19,860,292,957

Summary of the operating performance of subsidiaries and associates during the year

(i) According to the 13th Amendment to the Enterprise Registration Certificate dated 18 November 2025, the Company invested VND 700,000,000 in Hataphar Southern Company Limited, representing 48.28% of its charter capital. As of the end of the reporting period, the Company's investment remained VND 700,000,000, equivalent to 48.28% of the investee's charter capital.

(ii) According to the 5th Amendment to the Enterprise Registration Certificate dated 7 April 2026, the Company invested VND 9,800,000,000 in Hataphar Healthcare Vietnam High-Tech Pharmaceutical Joint Stock Company, representing 49% of its charter capital. As of the end of the reporting period, the Company held 49% of the investee's charter capital, equivalent to 980,000 shares of Hataphar Healthcare Vietnam High-Tech Pharmaceutical Joint Stock Company.

The associates have continued their normal business operations, with no significant changes compared with the previous reporting period.

As at 30 June 2026, the fair values of all the above investments could not be determined because there were no quoted market prices, or sufficient information was not available to reliably measure their fair values. Accordingly, the fair values of these investments may differ from their carrying amounts.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

3. Trade receivable

	30/6/2026		01/01/2026	
	VND		VND	
	Amount	Provision	Amount	Provision
a) Short-term	115,370,564,562	(3,100,934,958)	111,636,095,800	(3,169,473,494)
<i>- Some large balances in trade receivables:</i>				
Thanh Vinh Pharmaceutical and Medical Materials JSC	675,300,780	-	148,639,650	-
Thuan Anh Pharmaceutical Company Limited	1,090,011,240	-	5,779,512,102	-
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	22,792,015,259	-	40,103,925,920	-
Phap Au Pharmaceutical JSC	1,396,865,418	-	892,019,757	-
Duc Tam Company Limited	2,144,721,711	-	2,739,541,083	-
Vinh Gia Pharmaceutical JSC	2,905,018,231	-	1,064,753,077	-
Truong Huy Company Limited	3,896,430,151	-	2,969,374,918	-
Davinci – France Pharmaceutical Joint Stock	4,353,752,300	-	3,188,089,888	-
Danh Minh Pharmaceutical Joint Stock Company	5,681,272,550	-	3,780,248,320	-
Vinaplant Pharmaceutical JSC	7,671,070,464	-	6,973,025,318	-
Stabled Pharmaceutical Company Limited	1,605,899,700	-	884,881,615	-
Kim Long Investment JSC	1,186,387,324	-	1,657,733,296	-
Thu Duc City Hospital	1,774,525,000	(1,671,860,000)	1,774,525,000	(1,671,860,000)
T&T Equipment Joint Stock Company	3,517,653,670	-	9,799,671,420	-
Life Pharmaceutical and Medical Equipment Joint	-	-	1,738,670,425	-
Quang Cường Pharmaceutical Joint Stock Company	-	-	8,019,153,310	-
Dong Do Pharmaceutical Company Limited	27,868,489,018	-	-	-

4. Advances to suppliers

	30/6/2026	01/01/2026
	VND	VND
a) Short-term	42,456,270,278	37,840,076,173
<i>- Some large balances in Advances to suppliers:</i>		
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	773,730,167	1,830,521,186
Pharmametics products a division of max Biocare	12,586,762,100	2,573,704,006
Delta Pharma Ltd	1,516,328,464	7,846,059,364
Inbiotech l.t.d	646,177,815	6,997,520,425
Saifen Drugs Philippines Inc	3,584,185,500	2,840,549,628
Blis pharma distribution and Consultancy corp.	11,973,124,900	3,384,715,680

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

5. Other receivables	30/6/2026		01/01/2026	
	VND		VND	
	Amount	Provision	Amount	Provision
a) Short - term	474,879,091	-	294,439,301	-
Other receivables	131,935,186	-	163,462,990	-
Advances	342,943,905	-	130,976,311	-
Nguyen Van Phuc	100,000,000	-	-	-
Others	242,943,905	-	130,976,311	-
b) Long - term	6,407,042,500	-	6,407,042,500	-
Mortgages, deposits	6,407,042,500	-	6,407,042,500	-
Management Board of Hoa Lac High-Tech Park	6,407,042,500	-	6,407,042,500	-
Total	6,881,921,591	-	6,701,481,801	-

6. Bad debts	30/6/2026		01/01/2026	
	VND		VND	
	Cost	Recoverable amount	Cost	Recoverable amount
Total value of receivables, that are overdue and difficult to recover				
Accounts receivable	3,460,368,948	359,433,990	3,539,882,618	370,409,124
Thu Duc City Hospital	1,774,525,000	102,665,000	1,774,525,000	102,665,000
Others	1,685,843,948	256,768,990	1,765,357,618	267,744,124
Advances to suppliers	711,672,000	-	711,672,000	-
ERP Solutions Joint Stock Company	711,672,000	-	711,672,000	-
Total	4,172,040,948	359,433,990	4,251,554,618	370,409,124

7. Inventories	30/6/2026		01/01/2026	
	VND		VND	
	Cost	Provision	Cost	Provision
Purchased goods in transit	101,696,519,228	-	127,357,336,205	-
Raw materials	70,531,930,614	-	74,584,107,934	-
Tools and supplies	317,983,557	-	342,444,153	-
Work in progress	4,410,717,655	-	9,735,832,625	-
Finished goods	45,549,084,588	-	23,437,595,070	(1,961,049,751)
Goods	144,370,626,756	-	277,939,643,560	-
Total	366,876,862,398	-	513,396,959,547	(1,961,049,751)

HATAY PHARMACEUTICAL JOINT STOCK COMPANY

Address: No.10A Quang Trung Street, Ha Dong Ward, Hanoi City

CONSOLIDATED FINANCIAL STATEMENTS

For the period from 01/04/2026 to 30/06/2026

Form B 09a - DN/HN

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

8. Increases, decreases in tangible fixed assets

Items	Building and structures	Machinery, equipment	Means of transport, transmission equipment	Office equipment and tools	Other fixed assets	Total
Unit: VND						
Cost						
Balance as at 01/01/2026	168,479,750,526	259,122,286,133	13,999,342,253	4,451,386,943	439,282,500	446,492,048,355
Purchase in the year	-	1,152,439,000	-	-	138,687,000	1,291,126,000
Liquidation of fixed assets	-	(3,536,498,784)	-	-	-	(3,536,498,784)
Balance as at 30/06/2026	168,479,750,526	256,738,226,349	13,999,342,253	4,451,386,943	577,969,500	444,246,675,571
Accumulated depreciation						
Balance as at 01/01/2026	101,863,548,983	159,583,502,688	7,103,561,805	3,970,511,312	439,282,500	272,960,407,289
Depreciation in the year	3,652,956,964	8,139,146,657	496,454,151	71,554,921	-	12,360,112,693
Liquidation of fixed assets	-	(3,386,498,784)	-	-	-	(3,386,498,784)
Balance as at 30/06/2026	105,516,505,947	164,336,150,561	7,600,015,956	4,042,066,233	439,282,500	281,934,021,198
Net book value						
As at 01/01/2026	66,616,201,543	99,538,783,445	6,895,780,448	480,875,631	-	173,531,641,066
As at 30/6/2026	62,963,244,579	92,402,075,788	6,399,326,297	409,320,710	138,687,000	162,312,654,373

Form B 09a - DN/HN

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

9. Increases, decreases in intangible fixed assets

Unit: VND

Items	Accounting software	Land use rights	Total
Cost			
Balance as at 01/01/2026	650,000,000	1,376,660,000	2,026,660,000
Balance as at 30/06/2026	650,000,000	1,376,660,000	2,026,660,000
Accumulated amortization			
Balance as at 01/01/2026	650,000,000	-	650,000,000
Balance as at 30/06/2026	650,000,000	-	650,000,000
Net book value			
As at 01/01/2026	-	1,376,660,000	1,376,660,000
As at 30/06/2026	-	1,376,660,000	1,376,660,000

10. Construction in progress

	30/6/2026 VND	01/01/2026 VND
Hataphar High-Tech Pharmaceutical Factory	814,748,939,426	807,746,227,200
Bioequivalent cost	-	1,277,777,778
Purchasing fixed assets	925,925,926	925,925,926
Factory Renovation	6,356,077,756	2,674,508,863
Cost of research and development of pharmaceutical products	-	14,559,878,894
Total	822,030,943,108	827,184,318,661

11. Prepayments

	30/6/2026 VND	01/01/2026 VND
Long-term		
Issued tools and instruments awaiting for allocation	2,049,108,501	2,465,920,534
Cost of research and development of pharmaceutical products	12,959,907,530	-
Repair and renovation costs	4,959,151,727	2,858,499,091
Other Prepayments	222,222,222	307,754,625
Total	20,190,389,980	5,632,174,250

12. Deferred tax assets

	30/6/2026 VND	01/01/2026 VND
Corporate income tax rates are used to determine the value of deferred income tax assets.	20%	20%
Deferred income tax assets relate to deductible temporary differences.	1,043,333,673	1,185,726,662
Total	1,043,333,673	1,185,726,662

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

13. Trade payables

	30/6/2026 VND		01/01/2026 VND	
	Amount	Amount able to be paid off	Amount	Amount able to be paid off
Short - term	209,312,093,810	209,312,093,810	261,260,793,034	261,260,793,034
<i>- Some large balances in Trade payables:</i>				
Dong Au Trading and Production Company Limited	1,239,317,982	1,239,317,982	3,979,856,644	3,979,856,644
Vietnam Hataphar Healthcare High Technology Pharmaceutical JSC	4,480,596,669	4,480,596,669	5,817,834,883	5,817,834,883
KPC Pharmaceuticals, Inc	23,878,433,717	23,878,433,717	19,025,983,320	19,025,983,320
Wockhardt Limited	24,663,029,725	24,663,029,725	10,056,600,528	10,056,600,528
XL Laboratories PVT.,LTD	-	-	22,359,757,441	22,359,757,441
Pharmaunity Co.,Ltd	-	-	13,349,510,483	13,349,510,483
Pharmametics products a division of max Biocare	36,767,484,671	36,767,484,671	13,799,528,479	13,799,528,479
Delta Pharma Ltd	53,462,671,565	53,462,671,565	35,828,249,950	35,828,249,950
Blis pharma distribution and Consultancy corp.	-	-	40,758,864,060	40,758,864,060

14. Advances from customers

	30/6/2026 VND	01/01/2026 VND
Short - term	105,646,454,510	177,983,077,668
<i>- Some large balances in Advances from customers:</i>		
T&T Equipment Joint Stock Company	3,555,140,357	790,000,000
T&T Trading and Pharmaceutical Joint Stock Company	7,141,708,000	6,442,145,755
Thuan An Phat Pharmaceutical Joint Stock Company	-	10,784,000,000
Dong Do Pharmaceutical Company Limited	-	2,502,291,750
TB Vietnam Pharmaceutical Trading Company Limited	22,261,120,350	49,761,555,583
Vietlife Pharmaceutical Joint Stock Company	-	3,117,958,640
Hieu Anh Pharmaceutical Company Limited	9,616,136,453	8,045,259,000
Lam An Pharmaceutical Trading Company Limited	-	6,509,000,000
Tan Dai Cat Pharmaceutical Company Limited	2,151,864,000	-
Life Pharmaceutical and Medical Equipment Joint Stock Company	7,294,910,000	7,278,056,310
Dai Song Duong Biopharmaceutical Company Limited	7,898,230,375	9,028,478,251
California USA Pharmaceutical Company Limited	11,141,778,005	5,753,424,645
French Pharmaceutical Joint Stock Company	1,399,623,012	28,976,548,644

15. Taxes and amounts payable to the State budget

Unit: VND

Items	01/01/2026	Payable during the year	Paid during the year	30/6/2026
Payables				
Value added tax for domestic	841,144,007	8,549,361,579	9,351,599,336	38,906,250

Form B 09a - DN/HN

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

Items	01/01/2026	Payable during the year	Paid during the year	30/6/2026
Value added tax for import	-	38,887,044,652	38,887,044,652	-
Import and Export tax	-	4,927,630,446	4,927,630,446	-
Corporate income tax	4,550,220,339	5,215,244,396	6,693,175,871	3,072,288,864
Personal income tax	123,688,693	2,579,910,743	2,493,686,490	209,912,946
Land and housing tax, and land	-	101,203,055	101,203,055	-
Natural resource tax	-	11,926,600	11,926,600	-
Land rental fee	-	2,108,400,847	2,108,400,847	-
Total	5,515,053,039	62,380,722,318	64,574,667,297	3,321,108,060
16. Accrued expenses			30/6/2026	01/01/2026
			VND	VND
Short-term				
Interest payable			96,289,965	161,520,303
Total			96,289,965	161,520,303
17. Unearned revenue			30/6/2026	01/01/2026
			VND	VND
a) Short-term				
Deferred rental income from the lease of buildings and premises			658,524,989	575,370,229
Unrealised profit relating to inventories not yet sold to external parties by an associate arising from intercompany sales transactions			5,048,199,097	5,842,716,077
Total			5,706,724,086	6,418,086,306
18. Other payables			30/6/2026	01/01/2026
			VND	VND
a) Short-term			1,491,269,039	783,924,677
Insurance payables			441,612,917	592,397,733
Others			1,049,656,122	191,526,944
b) Long-term			3,486,900,000	3,625,600,000
Long term collaterals, deposits received			3,486,900,000	3,625,600,000
Total			4,978,169,039	4,409,524,677

CÔNG TY CP ĐƯỢC PHẨM HÀ TÂY

Address: No.10A Quang Trung Street, Ha Dong Ward, Hanoi City

CONSOLIDATED FINANCIAL STATEMENTS
For the period from 01/04/2026 to 30/06/2026

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

Form B 09a - DN/HN

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

19. Loans

	30/6/2026		In the period		01/01/2026	
	Amount	Amount able to be paid off	Increase	Decrease	Amount	Amount able to be paid off
a) Short-term	160,648,306,796	160,648,306,796	208,735,041,876	298,082,138,488	249,995,403,408	249,995,403,408
<i>a1) Short-term borrowing</i>	<i>146,803,598,871</i>	<i>146,803,598,871</i>	<i>208,735,041,876</i>	<i>298,082,138,488</i>	<i>236,150,695,483</i>	<i>236,150,695,483</i>
Vietnam Joint Stock Commercial Bank for Industry and Trade - Thanh An Branch	24,585,918,394	24,585,918,394	27,003,790,363	32,913,687,818	30,495,815,849	30,495,815,849
Joint Stock Commercial Bank For Foreign Trade Of Vietnam - West Hanoi Branch	26,712,876,010	26,712,876,010	43,712,034,371	79,311,770,320	62,312,611,959	62,312,611,959
Shinhan Bank Vietnam Limited - Hanoi Branch	28,365,590,146	28,365,590,146	67,966,495,110	91,651,765,953	52,050,860,989	52,050,860,989
Joint Stock Commercial Bank for Investment and Development of Vietnam - Ngoc Khanh Branch	25,886,584,460	25,886,584,460	39,059,765,677	37,583,085,462	24,409,904,245	24,409,904,245
Vietnam Bank for Agriculture and Rural Development- Ha Noi 2 Branch	19,791,268,800	19,791,268,800	21,118,721,175	22,160,803,244	20,833,350,869	20,833,350,869
Individuals	21,461,361,061	21,461,361,061	9,874,235,180	34,461,025,691	46,048,151,572	46,048,151,572
<i>a2) Long-term loans on due date</i>	<i>13,844,707,925</i>	<i>13,844,707,925</i>	-	-	<i>13,844,707,925</i>	<i>13,844,707,925</i>
MUFG Bank, Ltd., - Hanoi City Branch	13,844,707,925	13,844,707,925	-	-	13,844,707,925	13,844,707,925
b) Long-term	83,068,247,547	83,068,247,547	-	-	83,068,247,547	83,068,247,547
MUFG Bank, Ltd., - Hanoi City Branch	83,068,247,547	83,068,247,547	-	-	83,068,247,547	83,068,247,547
Total	243,716,554,343	243,716,554,343	208,735,041,876	298,082,138,488	333,063,650,955	333,063,650,955

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)*(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)***Form B 09a - DN/HN****20. Owner's equity****20.1 Movement in owner's equity**

Items	Owner's contributed capital	Share premium	Other capital	Treasury stock	Investment and development fund	Retained earnings	Non-controlling interest	Unit: VND Total
Balance as at 01/01/2025	823,417,730,000	97,320,000,000	26,612,306,630	(8,083,874,357)	10,749,248,213	79,530,817,489	27,214,093,742	1,056,760,321,717
Increase in Owner's Capital Contribution from Share Premium	60,037,780,000	(60,037,780,000)	-	-	-	-	-	-
Increase the owner's capital contribution from Retained earnings	22,300,000,000	-	-	-	-	(22,300,000,000)	-	-
Profit in the previous year	-	-	-	-	-	53,656,833,607	5,383,623,054	59,040,456,661
Decrease due to dividend distribution	-	-	-	-	-	-	(4,068,450,000)	(4,068,450,000)
Other decreases	-	-	-	-	-	(531,684,054)	-	(531,684,054)
Balance as at 31/12/2025	905,755,510,000	37,282,220,000	26,612,306,630	(8,083,874,357)	10,749,248,213	110,355,967,042	28,529,266,796	1,111,200,644,324
Transfer of Other Capital to Retained earnings accumulated to the prior year end (*)	-	-	(24,375,893,101)	-	-	24,375,893,101	-	-
Profit/Loss in this year	-	-	-	-	-	20,989,919,365	(598,778,643)	20,391,140,722
Other decreases	-	-	-	-	-	(615,094,063)	-	(615,094,063)
Balance as at 30/06/2026	905,755,510,000	37,282,220,000	2,236,413,529	(8,083,874,357)	10,749,248,213	155,106,685,445	27,930,488,153	1,130,976,690,983

(1) Transfer of Other Owners' Equity to Retained Earnings in accordance with Proposal No. 152/TTr-DHT dated 10 February 2026, which was approved under Resolution No. 219/NQ-DHT dated 30 March 2026 of the 2026 Annual General Meeting of Shareholders of Ha Tay Pharmaceutical Joint Stock Company.

(*) Carrying amount of shares in subsidiaries acquired from the parent company before 1 July 2015.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

20.2 Details of owner's equity

	30/6/2026	01/01/2026
	VND	VND
Hanoi City Development Investment Fund	34,076,520,000	34,076,520,000
ASKA Pharmaceutical Co.,Ltd	362,727,620,000	362,727,620,000
Le Van Lo	50,819,900,000	50,819,900,000
Ngo Van Chinh	22,195,920,000	22,195,920,000
Hoang Van Tue	36,153,210,000	36,153,210,000
Le Viet Linh	57,441,840,000	57,441,840,000
Nguyen Thi Minh Hau	1,725,100,000	1,725,100,000
Le Anh Trung	33,718,720,000	33,718,720,000
Le Xuan Thang	35,205,290,000	35,205,290,000
Ngo Tuan Viet	5,500,000,000	5,500,000,000
Others	266,191,390,000	266,191,390,000
Total	905,755,510,000	905,755,510,000

20.3 Capital transactions with owners, dividend distribution and shared profit

	Quarter II/2026	Quarter II/2025
	VND	VND
Owner's contributed capital	905,755,510,000	823,417,730,000
Contribution at the beginning of the period	905,755,510,000	823,417,730,000
Increase in the year	-	-
Contribution at the end of period	905,755,510,000	823,417,730,000
Paid dividend, shared profit	-	-

20.4 Shares

	30/6/2026	01/01/2026
	Shares	Shares
Number of shares registered for issue	90,575,551	90,575,551
Number of shares issued to the public	90,575,551	90,575,551
- Ordinary shares	90,575,551	90,575,551
Number of shares buyback	1,513	1,513
- Ordinary shares	1,513	1,513
Number of outstanding shares in circulation	90,574,038	90,574,038
- Ordinary shares	90,574,038	90,574,038
An ordinary share has par value of VND 10,000		

20.5 Dividends

Dividends declared after the end of the accounting period:

- Dividends declared on ordinary shares:

- Dividends declared on preferred stock: none

Unrecorded cumulative preferred stock dividends: none

21. Off Separate Balance Sheet items

	30/6/2026	01/01/2026
Foreign currencies		
USD	9,416.73	4,387.44
EUR	357.70	365.98

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

II. Additional information for items presented in the Consolidated Income Statement

1. Gross revenue from goods sold and services rendered

	Quater II/2026 VND	Quater II/2025 VND
Sale of finished goods	115,149,414,033	160,641,494,152
Sales of merchandises	460,790,285,591	413,918,629,392
Total	575,939,699,624	574,560,123,544

2. Deductions

	Quater II/2026 VND	Quater II/2025 VND
Returned goods	19,904,762	209,032,070
Total	19,904,762	209,032,070

3. Net revenue from goods sold and services rendered

	Quater II/2026 VND	Quater II/2025 VND
Net sale of finished goods	115,129,509,271	160,432,462,082
Net sales of merchandises	460,790,285,591	413,918,629,392
Total	575,919,794,862	574,351,091,474

4. Cost of goods sold

	Quater II/2026 VND	Quater II/2025 VND
Cost of finished goods sold	74,466,230,653	117,689,425,863
Cost of merchandise sold	449,567,134,513	405,028,419,586
Inventory disposal expenses	566,500,777	533,904,121
Total	524,599,865,943	523,251,749,570

5. Financial income

	Quater II/2026 VND	Quater II/2025 VND
Financial income incurred in the period	4,640,393,405	5,660,632,622
Total	4,640,393,405	5,660,632,622

6. Financial expenses

	Quater II/2026 VND	Quater II/2025 VND
Interest expense	2,880,294,497	3,430,297,452
Foreign exchange loss incurred during the period	510,040,430	6,016,941,650
Total	3,390,334,927	9,447,239,102

Form B 09a - DN/HN

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS (continued)

(These notes are an integral part of and should be read in conjunction with the accompanying Consolidated Financial Statements)

7. Other income

	Quater II/2026 VND	Quater II/2025 VND
Other income incurred in the period	3,479,113,615	3,790,770,741
Total	3,479,113,615	3,790,770,741

8. Other expenses

	Quater II/2026 VND	Quater II/2025 VND
Other expenses incurred in the period	771,185,302	1,198,831
Total	771,185,302	1,198,831

9. Selling expenses and general administration expenses

	Quater II/2026 VND	Quater II/2025 VND
a) Selling expenses incurred in the period	11,199,570,753	8,431,676,250
b) General administration expenses incurred in the period	29,745,837,357	28,489,882,488
Total	40,945,408,110	36,921,558,738

10. Current corporate income tax expenses

	Quater II/2026 VND	Quater II/2025 VND
Current corporate income tax expense based on taxable income for the current	3,632,813,461	2,928,429,738
Adjustment to current corporate income tax expense in respect of prior years	-	-
Total current corporate income tax expense	3,632,813,461	2,928,429,738


Hanoi, July 28, 2026

HATAY PHARMACEUTICAL JOINT STOCK COMPANY


Prepared by

Chief Accountant

General Director







Nguyen Hai Trieu

Dinh Nam Ha

Osamu Yomogida